watch cbsn live april 6 2020 5 06 am ap the new coronavirus made dr jag singh a patient at his own hospital his alarm grew as he saw an x ray of his pneumonia choked lungs and colleagues asked his wishes about life support while wheeling him into massachusetts general s intensive care unit when they offered him a chance to help test remdesivir an experimental drug that s shown promise against some other coronaviruses it did not even cross my mind once to say no said singh a heart specialist coronavirus patients around the world have been rushing to join remdesivir studies that opened in hospitals in the last few weeks interest has been so great that the u s national institutes of health is expanding its study which has nearly reached its initial goal of 440 patients the drug s maker california based gilead sciences is quickly ramping up its own studies too i would enroll my family in a heartbeat if the need arose said dr libby hohmann who placed singh and nearly 30 others in the nih one at mass general to have no approved medicines for covid 19 now is kind of terrifying she said remdesivir is given through an iv it s designed to interfere with an enzyme that reproduces viral genetic material in animal tests against sars and mers diseases caused by similar coronaviruses the drug helped prevent infection and reduced the severity of symptoms when given early enough in the course of illness it s farther along in testing than many other potential therapies and the current studies could lead to regulatory approval gilead has given remdesivir to more than 1 700 patients on a case by case emergency basis but more people ultimately will be helped if the company does the needed studies to prove safety and effectiveness chief executive dan o day wrote in a recent letter to the public many people have reached out to gilead to advocate for access to remdesivir on behalf of friends and loved ones i can only imagine how it must feel to be in that situation he wrote we are taking the ethical responsible approach in another letter on saturday o day said the company has 1 5 million doses which could mean more than 140 000 treatment courses depending on how long treatment needs to last the company is providing the drug for free for now and has set a goal of making 500 000 treatment courses by october and more than a million by the end of the year gilead supplied remdesivir for two studies in china expected to give results by the end of the month it also launched two studies for hospitalized patients in the u s asia europe and elsewhere one in severely ill patients tests five versus 10 days of treatment another in moderately sick patients compares those two options to standard care alone there s so much anxiety about the disease that the patients are quite interested and no one offered the chance has refused said dr arun sanyal the study leader at virginia commonwealth university in richmond the first patient he enrolled was a previously healthy middle aged man who had an out of state visitor a few days before his symptoms began what started as mild illness escalated to profound shortness of breath requiring supplemental oxygen at university hospitals cleveland medical center dr grace mccomsey has enrolled roughly half a dozen patients we re seeing more and more younger people like 30 really sick she said the nih study is the most rigorous test it compares remdesivir to placebo infusions and neither patients nor doctors know who is getting what until the end of the study besides the u s it s open in japan korea and singapore in chicago an 89 year old man was northwestern memorial hospital s first participant and the family was very excited to have him included said infectious diseases chief dr babafemi taiwo at the university of california irvine dr alpesh amin has enrolled several patients all are getting standard care even if they wind up getting a placebo rather than remdesivir amin said the boston cardiologist singh said he was willing to take that chance to advance science even if he personally winds up not benefiting he s now recovering at home after spending a week in the hospital the word placebo freaks some people out but rigorous testing is needed to avoid giving false hope or using something unsafe still it s tough to face patients with no proven therapy now hohmann said the worst thing is seeing some really young people who are really really sick such as a 49 year old man with three young children on life support she said that s pretty awful first published on april 6 2020 5 06 am 2020 the associated press all rights reserved this material may not be published broadcast rewritten or redistributed be in the know get the latest breaking news delivered straight to your inbox copyright 2020 cbs interactive inc all rights reserved 